Waters cortecs c18 column

Trastuzumab, pertuzumab, and Trastuzumab emtansine were purchased from Roche (Basel, Switzerland). Cetuximab and nivolumab were obtained from Bristol-Myers Squibb (New York, NY, USA). Pembrolizumab was provided by Merck & Co. (Kenilworth, NJ, USA). An anti-Ki-67 antibody (ab16667) was purchased from Abcam (Cambridge, UK).
Seventy-eight anticancer agents were tested in this study (Table S1). All compounds were dissolved in dimethyl sulfoxide at a concentration of 20 mM and stored at −80 °C until use. The purity and integrity of the compounds were measured via ultra-performance liquid chromatography-mass spectrometry (Waters Corporation, Milford, MA, USA), using a 1-µL injection volume, as follows. A Waters CORTECS C₁₈ column (particle size: 1.6 µm; column size: 2.1 × 50 mm; Waters Corporation) was developed with a linear aqueous acetonitrile (MeCN) gradient containing a 0.1% formic acid (5–90% MeCN, 1.6 min; flow rate, 1 mL/min), separation was performed at 40 °C, and the components of the major ultraviolet (UV) adsorption peaks were verified by mass spectrometry (Table S1).
Epidermal growth factor (EGF) and interferon-γ (IFN-γ) were obtained from Fujifilm Wako Pure Chemical, Ltd. (Osaka, Japan). Staphylococcal enterotoxin B (SEB) was obtained from Sigma-Aldrich (St. Louis, MO, USA).

All reagents and anhydrous solvents were obtained from commercial sources and used without further purification unless noted otherwise. All reactions involving air- or moisture-sensitive reagents were performed under a nitrogen atmosphere. ¹H-NMR spectra were obtained on an Agilent 400-MR DD2 with ONE_NMR probe actively shielded 400 MHz at 30°C. All final compounds were purified to ≥95% purity unless otherwise noted, as determined by HPLC-MS obtained on a Waters Acquity UPLC instrument using either [A] 2.1 x 30 mm Waters Cortecs C18 column (1.6 μm particles). [B] 2.1 x 30 mm Halo-2 C8 column (2μm particles). [C] 4.6 x 50 mm MAC-MOD Halo C8 column (2.7 μm particles). [D] 4.6 x 50 mm MAC-MOD Halo C18 column (2.7 μm particles). Detection methods were diode array (DAD) and evaporative light scattering (ELSD) detection as well as positive/negative electrospray ionization. Preparative HPLC-MS was performed on a Waters AutoPurification system using either [A] Phenomenex: Synergi MaxRP Prep, 4 μm particle size 19 x 150 mm column [B] Waters: Atlantis Prep T3 OBD, 5 μm particle size 50 x 100mm column [C] Phenomenex: Synergi Polar-RP 80A, 4 μm particle size 21.2 x 150 mm column.